$0.00
(Market cap
$4 Mln
Revenue (TTM)
$3 Mln
P/E Ratio
--
P/B Ratio
117.4
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-11 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.7
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.3
-
Face value
--
-
Shares outstanding
132,639,000
8 Years Aggregate
CFO
$-374.64 Mln
EBITDA
$-397.78 Mln
Net Profit
$-515.20 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Gamida Cell - ADR
| -95.9 | -- | -95.0 | -99.2 | -86.1 | -70.0 | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|
|
Gamida Cell - ADR
| -68.2 | -49.2 | -69.7 | 95.1 | -56.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Gamida Cell - ADR
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in... patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel. Read more
-
President, CEO & Director
Ms. Abigail L. Jenkins
-
President, CEO & Director
Ms. Abigail L. Jenkins
-
Headquarters
Jerusalem
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Gamida Cell - ADR
What is the current share price of Gamida Cell Ltd - ADR Today?
The share price of Gamida Cell Ltd - ADR is $0.02 (NASDAQ) as of 24-May-2024 09:30 EDT. Gamida Cell Ltd - ADR has given a return of -86.08% in the last 3 years.
What is the current PB & PE ratio of Gamida Cell Ltd - ADR?
Since, TTM earnings of Gamida Cell Ltd - ADR is negative, P/E ratio is not available.
The P/B ratio of Gamida Cell Ltd - ADR is 117.40 times as on 24-May-2024, a 2277 premium to its peers’ median range of 4.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-0.94 |
-20.08 |
2022 |
-0.62 |
-11.99 |
2021 |
-1.63 |
3.43 |
2020 |
-5.44 |
4.21 |
2019 |
-3.71 |
3.65 |
What is the 52 Week High and Low of Gamida Cell Ltd - ADR?
The 52-week high and low of Gamida Cell Ltd - ADR are Rs -- and Rs -- as of 31-Aug-2026.
What is the market cap of Gamida Cell Ltd - ADR?
Gamida Cell Ltd - ADR has a market capitalisation of $ 4 Mln as on 24-May-2024. As per SEBI classification, it is a company.
Should I invest in Gamida Cell Ltd - ADR?
Before investing in Gamida Cell Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.